Journal of the Chinese Medical Association 2009-01-01

Bartter's Syndrome with Type 2 Diabetes Mellitus

Ting-Ting See, Siu-Pak Lee

Index: J. Chin. Med. Assoc. 72(2) , 88-90, (2009)

Full Text: HTML

Abstract

We report a rare case of Bartter's syndrome in a 35-year-old woman with type 2 diabetes mellitus. The patient presented with leg weakness, fatigue, polyuria and polydipsia. Hypokalemia, metabolic alkalosis, and high renin and aldosterone concentrations were present, but the patient was normotensive. Gitelman's syndrome was excluded because of the presence of hypercalciuria, secondary hyperparathyroidism and bilateral nephrocalcinosis. The patient's condition improved upon administration of a prostaglandin synthetase inhibitor (acemetacin), oral potassium chloride and potassium-sparing diuretics. Five months later, the patient discontinued acemetacin because of epigastric discomfort; at the same time, severe hypokalemia and hyperglycemia developed. Glucagon stimulation and water deprivation tests were performed. Type 2 diabetes mellitus with nephrogenic diabetes insipidus was diagnosed. To avoid further gastrointestinal complications, the patient was treated with celecoxib, a selective cyclooxygenase 2 inhibitor. This case serves as a reminder that Bartter's syndrome is associated with various metabolic derangements including nephrogenic diabetes insipidus, nephrocalcinosis and diabetes mellitus. When treating Bartter's syndrome, it is also prudent to remember that the long-term use of nonsteroidal anti-inflammatory drugs and potassium-sparing diuretics may result in serious adverse reactions.


Related Compounds

  • acemetacin

Related Articles:

A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis.

2009-04-01

[Phlebology 24(2) , 56-60, (2009)]

A fast and reliable spectroscopic method for the determination of membrane--water partition coefficients of organic compounds.

2001-01-01

[Lipids 36(1) , 89-96, (2001)]

Multivariate optimization of separation conditions for simultaneous determination of acemetacin and chlorzoxazone in a pharmaceutical preparation by HPLC using response surface methodology.

2013-01-01

[J. AOAC Int. 96(4) , 723-9, (2013)]

Pharmacokinetics of acemetacin and its active metabolite indomethacin in rats during acute hepatic damage and liver regeneration.

2009-01-01

[Ann. Hepatol. 8(2) , 141-7, (2009)]

[Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib].

2004-09-01

[Orthopade. 33(9) , 1032-41, (2004)]

More Articles...